94,90 €
A modern and practical dosing pen designed for precise and convenient administration of research compounds. Its elegant design, compact construction, and user-friendly operation allow efficient handling in laboratory environments. BPC-157 + TB-500 is a highly concentrated, premium research combination of two reparative peptides in an optimal 1:1 ratio (10 mg + 10 mg). The combination of two distinct mechanisms of action—growth factor stimulation and actin upregulation—creates a maximum synergistic effect that is the subject of intensive scientific research in the fields of accelerated musculoskeletal healing, angiogenesis, and systemic inflammation suppression. Needles are not included in the package and are not available in our product range. The product is intended exclusively for scientific and research purposes.
4 in stock
The combination of BPC-157 and TB-500 represents the absolute pinnacle of regenerative medicine and traumatology research. This product combines two of the most significant reparative molecules in a precise ratio of 10 mg BPC-157 (Body Protection Compound) and 10 mg TB-500 (Thymosin Beta-4) in 2 ml of solution. In scientific models, this combination is studied together due to their complementary biological mechanisms: while BPC-157 excels at localized restoration of cellular connections and mucosal protection, TB-500, thanks to its low molecular weight, acts systemically and accelerates the migration of reparative cells directly to sites of injury.
The dosing pen contains a total of 20 mg of highly purified compounds in 2 ml of solution, providing a high overall concentration of 10 mg/ml (5 mg/ml BPC-157 + 5 mg/ml TB-500). Calculated for precise dosing within research protocols:
1 ml = 100 units (IU) = 100 clicks
0.5 ml (one full rotation of the mechanism) = 50 clicks
Examples of mixture dosing (BPC-157 + TB-500) for research purposes:
1 click = 0.10 mg (100 mcg mixture = 50 mcg BPC-157 + 50 mcg TB-500)
2 clicks = 0.20 mg (200 mcg mixture = 100 mcg BPC-157 + 100 mcg TB-500)
5 clicks (0.05 ml) = 0.50 mg (500 mcg mixture = 250 mcg BPC-157 + 250 mcg TB-500)
10 clicks (0.1 ml) = 1.00 mg (1000 mcg mixture = 500 mcg BPC-157 + 500 mcg TB-500)
20 clicks (0.2 ml) = 2.00 mg (2000 mcg mixture = 1000 mcg BPC-157 + 1000 mcg TB-500)
This mechanical system guarantees absolute precision, repeatability, and flexibility when adjusting doses according to the requirements of a specific laboratory protocol without the need for complex manual mixing of two separate lyophilized vials.
Research-Studied Effects
The fundamental focus of research on this fixed combination is its synergy in the processes of angiogenesis and cellular migration. BPC-157 upregulates growth factor receptors (VEGFR2), thereby signaling the formation of new microvessels. At the same time, TB-500 activates actin polymerization, a cytoskeletal protein, allowing fibroblasts and endothelial cells to migrate extremely rapidly through these newly formed pathways directly to the site of injury.
In in vivo studies, this combination has demonstrated unprecedented results in the repair of severe musculoskeletal injuries—accelerating the healing of torn muscles, damaged articular cartilage, chronic tendon inflammation (tendinitis), and ligaments. TB-500 helps prevent the formation of rigid scar tissue (fibrosis), while BPC-157 protects cellular integrity and significantly reduces both systemic and local inflammatory markers. This comprehensive approach ensures that regenerated tissue retains its original elasticity, strength, and full functionality.
Scientific Context and References
The combined effect of angiogenesis stimulators and actin modulators is the subject of intensive interest in modern biomedical research available through the respected international PubMed database. Research studies confirm that simultaneous administration of both peptides results in a significantly higher rate of cellular proliferation compared to their individual use.
Comprehensive data regarding pharmacokinetics, tissue tolerance, and the effects of this combination on Type I and Type III collagen expression are continuously monitored and collected through clinical study proposals listed on ClinicalTrials.gov, where this combination serves as a key model for the development of future advanced therapies in sports medicine, orthopedics, and traumatology.
The Royal Peptides dosing pen provides a modern, safe, and highly sterile solution for handling this advanced molecular blend under controlled laboratory conditions.
The product is intended exclusively for scientific and research purposes. Not for direct human consumption.
